RKS262 (CAS: 1041469-97-9)
Background Information of RKS262
RKS262 is a CDK1/4 inhibitor.
Storage Condition of RKS262
Quality Control and Spectral Data
Mechanism and Indications
||Sponsor & Collaborators
||RKS262; RKS 262; RKS-262
Structure Information of RKS262
Other Form Products of RKS262
Recommended Products in Same Target
Recommended Products in the Same Indication
Chemical and Physical Properties
||Solubility:Soluble in DMSO
.Tutone M, et al. Recent advances on CDK inhibitors: An insight by means of in silico methods. Eur J Med Chem. 2017 Dec 15;142:300-315.
The cyclin dependent kinases (CDKs) are a small family of serine/threonine protein kinases that can act as a potential therapeutic target in several proliferative diseases, including cancer. This short review is a survey on the more recent research progresses in the field achieved by using in silico methods. All the "armamentarium" available to the medicinal chemists (docking protocols and molecular dynamics, fragment-based, de novo design, virtual screening, and QSAR) has been employed to the discovery of new, potent, and selective inhibitors of cyclin dependent kinases. The results cited herein can be useful to understand the nature of the inhibitor-target interactions, and furnish an insight on the structural/molecular requirements necessary to achieve the required selectivity against cyclin dependent kinases over other types of kinases.